Depressive symptoms and antiretroviral therapy (ART) initiation among HIV-infected russian drinkers

AIDS and Behavior

Volumn 18, Issue 6, 2014, Pages 1085-1093

  Goodness, Tracie M ^a   Palfai, Tibor P ^a   Cheng, Debbie M ^b   Coleman, Sharon M ^a   Bridden, Carly ^b,c   Blokhina, Elena ^d   Krupitsky, Evgeny ^e   Samet, Jeffrey H ^a  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^e Bekhterev St Petersburg Psychoneurological Research Institute   (Russian Federation)

Author keywords

Antiretroviral therapy (ART); Depressive symptoms; HIV; Russia

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEPRESSION; DRINKING BEHAVIOR; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HIV INFECTIONS; HUMAN; MALE; MEDICATION COMPLIANCE; PSYCHOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE;

ADULT; ALCOHOL DRINKING; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; QUESTIONNAIRES; RUSSIA; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84905561785     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-013-0674-y     Document Type: Article

References (56)

1. Pence BW, O'Donnell JK, Gaynes BN. Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. AIDS. 2012;26(5):656-8.
2. Eller LS, Bunch EH, Wantland DJ, et al. Prevalence, correlates, and self-management of HIV-related depressive symptoms. AIDS Care. 2010;22(9):1159-70.
3. Cruess DG, Petitto JM, Leserman J, et al. Depression and HIV infection: impact on immune function and disease progression. CNS Spectr. 2003;8(1):52-8.
4. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA. 2001;285(11):1466-74.
5. Leserman J, Petitto JM, Golden RN, et al. Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS. Am J Psychiatry. 2000;157(8):1221-8.
6. Leserman J, Whetten K, Lowe K, Stangl D, Swartz MS, Thielman NM. How trauma, recent stressful events, and PTSD affect functional health status and health utilization in HIV-infected patients in the south. Psychosom Med. 2005;67(3):500-7.
7. Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med. 2008;70(5):539-45.
8. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retrovir. 2010;26(5):511-8.
9. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16(2):83-8.
10. Spies G, Asmal L, Seedat S. Cognitive-behavioural interventions for mood and anxiety disorders in HIV: a systematic review. J Affect Disord. 2013;150(2):171-80.
11. O'Cleirigh C, Skeer M, Mayer KH, Safren SA. Functional impairment and health care utilization among HIV-infected men who have sex with men: the relationship with depression and post-traumatic stress. J Behav Med. 2009;32(5):466-77.
12. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and metaanalysis. J Acquir Immune Defic Syndr. 2011;58(2):181-7.
13. Gore-Felton C, Koopman C. Behavioral mediation of the relationship between psychosocial factors and HIV disease progression. Psychosom Med. 2008;70(5):569-74.
14. Safren SA, O'Cleirigh CM, Bullis JR, OttoMW,Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80(3):404-15.
15. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.AIDSinfo.nih.gov/contentfiles/lvguidelines/adultand adolescentgl.pdf. Accessed 30 Aug 2012.
16. Holmberg SD, Palella FJ Jr, Lichtenstein KA, Havlir DV. The case for earlier treatment of HIV infection. Clin Infect Dis. 2004;39(11):1699-704.
17. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment OST). Int J Drug Policy. 2007;18(4):262-70.
18. Himelhoch S, Moore RD, Treisman G, Gebo KA. Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy? J Acquir Immune Defic Syndr. 2004;37(4):1457-63.
19. Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008;22(3):233-43.
20. Fairfield KM, Libman H, Davis RB, Eisenberg DM. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14(7):395-401.
21. Sambamoorthi U, Walkup J, Olfson M, Crystal S. Antidepressant treatment and health services utilization among HIV-infected Medicaid patients diagnosed with depression. J Gen Intern Med. 2000;15(5):311-20.
22. Murray LK, Semrau K, McCurley E, et al. Barriers to acceptance and adherence of antiretroviral therapy in urban Zambian women: a qualitative study. AIDS Care. 2009;21(1):78-86.
23. Kalichman SC, Graham J, Luke W, Austin J. Perceptions of health care among persons living with HIV/AIDS who are not receiving antiretroviral medications. AIDS Patient Care STDS. 2002;16(5):233-40.
24. Bhatia R, Hartman C, Kallen MA, Graham J, Giordano TP. Persons newly diagnosed with HIV infection are at high risk for depression and poor linkage to care: results from the steps study. AIDS Behav. 2011;15(6):1161-70.
25. Martinez P, Andia I, Emenyonu N, et al. Alcohol use, depressive symptoms and the receipt of antiretroviral therapy in southwest Uganda. AIDS Behav. 2008;12(4):605-12.
26. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic, 2010. http://www.unAIDS.org/ documents/20101123-GlobalReport-em.pdf. Accessed 30 Aug 2012.
27. Samet JH. Russia and human immunodeficiency virus-beyond crime and punishment. Addiction. 2011;106(11):1883-5.
28. Baliunas D, Rehm J, Irving H, Shuper P. Alcohol consumption and risk of incident human immunodeficiency virus infection: a meta-analysis. Int J Public Health. 2010;55(3):159-66.
29. Drumright LN, Patterson TL, Strathdee SE. Club drugs as causal risk factors for HIV acquisition among men who have sex with men: a review. Subst Use Misuse. 2006;41(10-12):1551-601.
30. Maisto SA, Carey MP, Carey KB, Gordon CM. The effects of alcohol and expectancies on risk perception and behavioral skills relevant to safer sex among heterosexual young adult women. J Stud Alcohol. 2002;63(4):476-85.
31. Kalichman SC, Simbayi LC, Vermaak R, Jooste S, Cain D. HIV/AIDS risks among men and women who drink at informal alcohol serving establishments (Shebeens) in Cape Town, South Africa. Prev Sci. 2008;9(1):55-62.
32. Fromme K, Katz E, D'Amico E. Effects of alcohol intoxication on the perceived consequences of risk taking. Exp Clin Psychopharmacol. 1997;5(1):14-23.
33. Prause N, Staley C, Finn P. The effects of acute ethanol consumption on sexual response and sexual risk-taking intent. Arch Sex Behav. 2011;40(2):373-84.
34. George WH, Davis KC, Norris J, et al. Indirect effects of acute alcohol intoxication on sexual risk-taking: the roles of subjective and physiological sexual arousal.Arch Sex Behav. 2009;38(4):498-513.
35. Safika I, Johnson TP, Levy JA. A venue analysis of predictors of alcohol use prior to sexual intercourse among female sex workers in Senggigi, Indonesia. Int J Drug Policy. 2011;22(1):49-55.
36. Boden JM, Fergusson DM, Horwood LJ. Alcohol and STI risk: Evidence from a new zealand longitudinal birth cohort. Drug Alcohol Depend. 2011;113(2-3):200-6.
37. Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178-93.
38. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;37(9738):355-66.
39. Sarang A, Rhodes T, Sheon N, Page K. Policing drug users in Russia: risk, fear, and structural violence. Subst Use Misuse. 2010;45(6):813-64.
40. Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory-II. San Antonio: Psychological Corporation; 1996.
41. Kalichman SC, Rompa D, Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV/AIDS. J Nerv Ment Dis. 2000;188(10): 662-70.
42. Beck AT. Depression inventory, Beck. Russian translation. Aaron T. Beck: Pearson Education, Inc.; 1996. 2007.
43. Steer RA, Ball R, Ranieri WF, Beck AT. Dimensions of the beck depression inventory-II in clinically depressed outpatients. J Clin Psychol. 1999;55(1):117-28.
44. World Health Organization. Gender and women's mental health. http://www.who.int/mental-health/prevention/genderwomen/en. Accessed 28 March 2013.
45. Weatherby NL, Needle R, Cesari H, et al. Validity of selfreported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Program Plann. 1994;17(4):347-55.
46. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported ethanol consumption. Totowa: Humana Press; 1992.
47. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Moderate & binge drinking. http://www.niaaa.nih.gov/alcoholhealth/overview-alcohol- consumption/moderate-binge-drinking. Accessed 15 Dec 2012.
48. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med. 1999;14(5):267-73.
49. Diggle P, Liang KY, Zeger SL. Analysis of longitudinal data. New York: Clarendon Press; Oxford University Press; 1995.
50. SAS Institute Inc. SAS/STAT-9.2. 2008.
51. Tran BX, Ohinmaa A, Duong AT, et al. Changes in drug use are associated with health-related quality of life improvements among methadone maintenance patients with HIV/AIDS. Qual Life Res. 2012;21(4):613-23.
52. Chander G, Himelhoc S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs. 2006;66(6):769-89.
53. Sullivan LE, Saitz R, Cheng DM, Libman H, Nunes D, Samet JH. The impact of alcohol use on depressive symptoms in human immunodeficiency virus-infected patients. Addiction. 2008; 103(9):1461-7.
54. Farley J, Miller E, Zamani A, et al. Screening for hazardous alcohol use and depressive symptomatology among HIV-infected patients in Nigeria: prevalence, predictors, and association with adherence. J Int Assoc Physicians AIDS Care (Chic). 2010;9(4): 218-26.
55. Ferguson CJ, Stanley M, Souchek J, Kunik ME. The utility of somatic symptoms as indicators of depression and anxiety in military veterans with chronic obstructive pulmonary disease. Depress Anxiety. 2006;23(1):42-9.
56. Basu S, Chwastiak LA, Bruce RD. Clinical management of depression and anxiety in HIV-infected adults. AIDS. 2005; 19(18):2057-67.